Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation

Peroxisome proliferator-activated receptor γ (PPARγ) is a major therapeutic target for the treatment of type 2 diabetes. However, the use of PPARγ-targeted drugs, such as rosiglitazone and pioglitazone, is limited owing to serious side effects caused by classical agonism. Using a rational drug disco...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Jang, Jun Young, Kim, Hyunsoo, Kim, Hyun-Jung, Suh, Se Won, Park, Seung Bum, Han, Byung Woo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6671948/
https://ncbi.nlm.nih.gov/pubmed/31371757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-47672-w
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller